지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2022.1
- 수록면
- 301 - 313 (13page)
- DOI
- 10.4143/crt.2020.1371
이용수
초록· 키워드
오류제보하기
Purpose There are unmet needs associated with the current treatment strategies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) due to the poor treatment outcomes of these strategies. Roflumilast, a selective phosphodiesterase-4 inhibitor used for treating chronic obstructive pulmonary disease, is effective against B-cell malignancy via phosphoinositide 3-kinase (PI3K)?activity suppression. We analyzed the effects of roflumilast combined with ESHAP (etoposide, cisplatin, methylprednisolone, and cytarabine) chemotherapy in experimental and clinical settings.Materials and Methods An in vitro study using lymphoma cell lines and a pilot study on relapsed/refractory DLBCL patients were conducted to investigate the effects and mechanism of the combination of roflumilast and chemotherapy. The complete response (CR), overall response rate (ORR), and 1-year progression-free survival (PFS) were analyzed.Results We found that roflumilast is efficient when combined with other chemotherapy drugs, especially cytarabine. Synergistic effects between these two drugs influence the translation of mammalian target of rapamycin and myeloid cell leukemia 1, resulting in apoptosis and inhibition of B-cell lymphoma proliferation. In clinical setting, the roflumilast group showed better rates of CR (46.2% vs. 34.6%), ORR (76.9% vs. 53.8%), and 1-year PFS (50.0% vs. 25.9%) compared with the control group, though not statistically significant. The roflumilast group showed a higher incidence of asthenia and gastrointestinal adverse events. However, grade 3 or 4 adverse events were similar in both groups.Conclusion We found that roflumilast, when combined with ESHAP chemotherapy, for relapsed/refractory DLBCL was clinically active and well tolerated. This combined treatment was able to suppress PI3K activity, which is correlated with the degree of clinical response.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
Cancer Research and Treatment
2023 .01
-
Salvage treatment of relapsed/refractory LCH
Blood Research
2016 .01
-
Clinicopathological characteristics and treatment outcomes of 38 cases of primary thyroid ymphoma : a multicenter study
Annals of Surgical Treatment and Research
2015 .11
-
Chemotherapy : Is it needed?
대한외과학회 학술대회 초록집
2015 .11
-
Comparison of Efficacy of Pembrolizumab between Epstein-Barr VirusPositive and Negative Relapsed or Refractory Non-Hodgkin Lymphomas
Cancer Research and Treatment
2019 .01
-
Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma
Blood Research
2019 .01
-
원발성 위장관 림프종의 수술 후 복합 화학요법과 화학요법 단독과의 비교: 단일 기관 연구
고신대학교 의과대학 학술지
2015 .01
-
Salvage chemotherapy with R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) for the treatment of relapsed primary CNS lymphoma
Blood Research
2016 .01
-
Genomics of diffuse large B cell lymphoma
Blood Research
2021 .04
-
Genomics of diffuse large B cell lymphoma
Blood Research
2021 .01
-
Clinicopathologic implication of PD-L1 gene alteration in primary adrenal diffuse large B cell lymphoma
Journal of Pathology and Translational Medicine
2022 .01
-
An Elevated Platelet Count Increases the Risk of Relapse in Ulcerative Colitis Patients with Mucosal Healing
Gut and Liver
2018 .01
-
Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma
Blood Research
2017 .01
-
Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma
Cancer Research and Treatment
2022 .10
-
췌장 및 담도암 환자의 항암 시작, 반응 평가 및 항암 중단 시점
대한췌담도학회지
2020 .01
-
Relapse of Ocular Lymphoma following Primary Testicular Diffuse Large B-cell Lymphoma
Journal of Retina
2023 .05
-
비부비동 악성 림프종에 대한 임상고찰: 치료방침 및 예후인자
대한이비인후-두경부외과학회지
2024 .09
-
Two Cases of Adjuvant Immunotherapy with Cytokine-Induced Killer Cells for Relapsed or Refractory Neuroblastoma
Clinical Pediatric Hematology-Oncology
2018 .01
-
미만성 거대 B세포 림프종의 중추신경계 재발 후 장기 생존한 2예
대한내과학회지
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0